Clinical Trials Logo

Filter by:
NCT ID: NCT06295926 Not yet recruiting - Clinical trials for Small Cell Lung Cancer

Serplulimab Combined With CCRT for LS-SCLC.

Start date: February 25, 2024
Phase: Phase 2
Study type: Interventional

Small cell lung cancer(SCLC) has a poor prognosis and a relatively short overall survival time, urgently requiring innovative treatment strategies to improve the prognosis of such patients. Immunotherapy has become an important component of first-line therapy for extensive-stage small cell lung cancer (ES-SCLC). Studies have found that, compared to chemotherapy alone, the combination of Surlidumab with carboplatin and etoposide can extend the median overall survival in ES-SCLC to over 15 months. However, to date, research on the use of immunotherapy in combination with concurrent chemoradiotherapy (CCRT) in limited-stage small cell lung cancer (LS-SCLC) remains limited. This study aims to explore the clinical benefits of Surlidumab in combination with concurrent chemoradiotherapy in LS-SCLC and evaluate the safety of immunotherapy in combination with CCRT as first-line treatment for LS-SCLC. At the same time, it seeks to identify tumor-related biomarkers that can effectively predict the efficacy of immunotherapy and prognosis.

NCT ID: NCT06294691 Not yet recruiting - Clinical trials for Acute Graft-versus-host Disease

Effect of Stem Cell Infusion Time on aGVHD in Patients With Nonmalignant Hematologic Diseases

Start date: March 1, 2024
Phase: Phase 3
Study type: Interventional

To observe the effect of stem cell infusion on the development of acute graft- versus-host disease (aGVHD) in patients with nonmalignant hematologic diseases after allogeneic peripheral blood hematopoietic stem cell transplantation (allo-PBSCT)

NCT ID: NCT06294678 Not yet recruiting - Clinical trials for Acute Graft-versus-host Disease

Effect of Stem Cell Infusion Time on aGVHD in Patients With Hematological Malignancies

Start date: March 1, 2024
Phase: Phase 3
Study type: Interventional

To observe the effect of stem cell infusion on the development of acute graft-versus-host disease (aGVHD) in patients with malignant hematologic diseases after allogeneic peripheral blood hematopoietic stem cell transplantation (allo-PBSCT)

NCT ID: NCT06293716 Not yet recruiting - Clinical trials for PI3K and P110delta Hyperactivation Syndrome

CVL237 Tablets for APDS/PASLI

Start date: March 30, 2024
Phase: Phase 2/Phase 3
Study type: Interventional

This study was designed to evaluate the efficacy and safety of CVL237 tablets in patients with APDS/PASLI (activated phosphoinositol 3-kinase δ syndrome /p110 delta-activated mutation leading to senescent T cells, lymphadenopathy, and immune deficiency).

NCT ID: NCT06293690 Not yet recruiting - Clinical trials for Non-small Lung Cancer

Toripalimab Combined With SBRT for NSCLC

Start date: March 15, 2024
Phase: Phase 2
Study type: Interventional

This study aimed to evaluate the efficacy and safety of Toripalimab injection (js001) combined with SBRT radiotherapy and neoadjuvant therapy with or without chemotherapy for operable or potentially operable stage IIa to IIIb NSCLC

NCT ID: NCT06292988 Not yet recruiting - Clinical trials for Medullary Thyroid Cancer

Predictive Factors for Medullary Thyroid Cancer Aggressiveness

MYELO
Start date: March 1, 2024
Phase:
Study type: Observational

This study is a retrospective study trying to find the predictive factors for medullary thyroid aggressiveness in terms of tumor metastasis and patients' survival.

NCT ID: NCT06292689 Not yet recruiting - Clinical trials for Vulvar and Vaginal Cancer

A Phase II, Single-arm, Multicenter, Prospective Study of Cardunolizumab in Recurrent or Metastatic Vulvar and Vaginal Cancer

Start date: March 22, 2024
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy and safety of cardunolizumab in combination with/without chemotherapy ± bevacizumab for recurrent or metastatic vulvar and vaginal cancers that are not amenable to radical treatment.

NCT ID: NCT06292650 Not yet recruiting - Clinical trials for Retinitis Pigmentosa

Safety and Efficacy Study of Novel Gene Therapy ZM-02 for Retinitis Pigmentosa Patients

ZM-02
Start date: February 25, 2024
Phase: Early Phase 1
Study type: Interventional

This trial is meant to evaluate the safety and efficacy of ZM-02 in Retinitis pigmentosa (RP) patients. Unilateral intravitreal injections (IVT) will be given into the subject's Study Eye.

NCT ID: NCT06292585 Not yet recruiting - Clinical trials for Traumatic Brain Injury

Acute EpiDural Hematoma Treated With Middle Meningeal Artery Embolization: a Randomized Trial (AEDH-MT)

Start date: March 2024
Phase: N/A
Study type: Interventional

A prospective, multicenter, randomized controlled, open-label, blinded endpoint evaluation study.

NCT ID: NCT06289959 Not yet recruiting - Clinical trials for Lymphoma, Large B-Cell, Diffuse

Plasma cfDNA Testing Guiding the Treatment Decisions of DLBCL

Start date: February 25, 2024
Phase: N/A
Study type: Interventional

A prospective, single center, randomized, clinical controlled study to evaluate the efficacy and prognosis differences between precision treatment based on plasma cfDNA testing results and the current conventional diagnostic and treatment practices for DLBCL patients.